» Articles » PMID: 35799833

Modeling Pandemic to Endemic Patterns of SARS-CoV-2 Transmission Using Parameters Estimated from Animal Model Data

Overview
Journal PNAS Nexus
Specialty General Medicine
Date 2022 Jul 8
PMID 35799833
Authors
Affiliations
Soon will be listed here.
Abstract

The contours of endemic coronaviral disease in humans and other animals are shaped by the tendency of coronaviruses to generate new variants superimposed upon nonsterilizing immunity. Consequently, patterns of coronaviral reinfection in animals can inform the emerging endemic state of the SARS-CoV-2 pandemic. We generated controlled reinfection data after high and low risk natural exposure or heterologous vaccination to sialodacryoadenitis virus (SDAV) in rats. Using deterministic compartmental models, we utilized in vivo estimates from these experiments to model the combined effects of variable transmission rates, variable duration of immunity, successive waves of variants, and vaccination on patterns of viral transmission. Using rat experiment-derived estimates, an endemic state achieved by natural infection alone occurred after a median of 724 days with approximately 41.3% of the population susceptible to reinfection. After accounting for translationally altered parameters between rat-derived data and human SARS-CoV-2 transmission, and after introducing vaccination, we arrived at a median time to endemic stability of 1437 (IQR = 749.25) days with a median 15.4% of the population remaining susceptible. We extended the models to introduce successive variants with increasing transmissibility and included the effect of varying duration of immunity. As seen with endemic coronaviral infections in other animals, transmission states are altered by introduction of new variants, even with vaccination. However, vaccination combined with natural immunity maintains a lower prevalence of infection than natural infection alone and provides greater resilience against the effects of transmissible variants.

Citing Articles

Dynamic Changes in Lymphocyte Populations and Their Relationship with Disease Severity and Outcome in COVID-19.

Andrejkovits A, Hutanu A, Manu D, Dobreanu M, Vasiesiu A Int J Mol Sci. 2024; 25(22).

PMID: 39595989 PMC: 11593669. DOI: 10.3390/ijms252211921.


Reducing opioid related deaths for individuals who are at high risk of death from overdose: a co-production study with people housed within prison and hostel accommodation during Covid-19.

Campbell A, Millen S, Guo L, Jordan U, Taylor-Beswick A, Rintoul C Front Public Health. 2023; 11:1080629.

PMID: 37404271 PMC: 10316785. DOI: 10.3389/fpubh.2023.1080629.


Stratification of COVID-19 Severity Using SeptiCyte RAPID, a Novel Host Immune Response Test.

Gravrand V, Mellot F, Ackermann F, Ballester M, Zuber B, Kirk J Viruses. 2023; 15(2).

PMID: 36851633 PMC: 9960895. DOI: 10.3390/v15020419.


SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies.

Beukenhorst A, Koch C, Hadjichrysanthou C, Alter G, de Wolf F, Anderson R Eur J Epidemiol. 2023; 38(3):237-242.

PMID: 36738380 PMC: 9898703. DOI: 10.1007/s10654-023-00965-x.


A C57BL/6 Mouse Model of SARS-CoV-2 Infection Recapitulates Age- and Sex-Based Differences in Human COVID-19 Disease and Recovery.

Davis M, Voss K, Turnbull J, Gustin A, Knoll M, Muruato A Vaccines (Basel). 2023; 11(1).

PMID: 36679892 PMC: 9860616. DOI: 10.3390/vaccines11010047.


References
1.
Johansson M, Quandelacy T, Kada S, Prasad P, Steele M, Brooks J . SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Netw Open. 2021; 4(1):e2035057. PMC: 7791354. DOI: 10.1001/jamanetworkopen.2020.35057. View

2.
Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S . Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10.... MMWR Morb Mortal Wkly Rep. 2022; 71(7):255-263. PMC: 8853475. DOI: 10.15585/mmwr.mm7107e2. View

3.
Akimkin V, Beer M, Blome S, Hanke D, Hoper D, Jenckel M . New Chimeric Porcine Coronavirus in Swine Feces, Germany, 2012. Emerg Infect Dis. 2016; 22(7):1314-5. PMC: 4918154. DOI: 10.3201/eid2207.160179. View

4.
Bushman M, Kahn R, Taylor B, Lipsitch M, Hanage W . Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. Cell. 2021; 184(26):6229-6242.e18. PMC: 8603072. DOI: 10.1016/j.cell.2021.11.026. View

5.
Davis C, Logan N, Tyson G, Orton R, Harvey W, Perkins J . Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog. 2021; 17(12):e1010022. PMC: 8639073. DOI: 10.1371/journal.ppat.1010022. View